Скачать или смотреть Recap of Australia Pavilion at BIO Asia–Taiwan 2025

At BIO Asia–Taiwan 2025, the Australia Pavilion brought together 24 leading organizations to highlight Australia’s unique advantages as a clinical trials destination and the technologies transforming the future of drug development. 🇦🇺

Throughout the event, companies demonstrated capabilities in:
1. Early-phase and multi-site clinical trial execution
2. Biomarker discovery, immunology, and assay development
3. Digital and decentralized trial models
4. GMP manufacturing, CDMO services, and supply chain logistics
5. Regulatory strategy and R&D tax incentive support

These capabilities reflect the strengths outlined in the latest MTPConnect sector report, which highlights how Australia enables rapid trial start-up through streamlined ethics and regulatory pathways, such as the Clinical Trial Notification (CTN) scheme. With high-quality, globally accepted data, a competitive R&D environment supported by government incentives, and access to a diverse patient population underpinned by advanced research infrastructure, Australia remains an ideal location for conducting clinical trials.

With a track record of delivering reliable, efficient, and scalable clinical research, Australia continues to serve as a trusted partner for global biopharma innovation.

More exclusive content here: https://lnkd.in/dXtSXZ5